Insiders Buying Zevra Therapeutics And 1 Other Stock
Portfolio Pulse from Avi Kapoor
Insiders have recently purchased shares in Zevra Therapeutics and Citi Trends, indicating confidence in these companies' prospects. Zevra Therapeutics' CFO acquired 2,000 shares, while a 10% owner of Citi Trends acquired 3,000 shares. These insider trades suggest potential buying opportunities.
July 18, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citi Trends' 10% owner Pleasant Lake Partners LLC acquired 3,000 shares at an average price of $20.06, indicating confidence in the company's prospects. The company also posted a narrower-than-expected quarterly loss on June 4.
The insider purchase by a significant shareholder indicates confidence in the company's future. The recent narrower-than-expected quarterly loss further supports a positive outlook, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Zevra Therapeutics' CFO & Treasurer R. Laduane Clifton acquired 2,000 shares at an average price of $6.77, indicating confidence in the company's prospects. Additionally, HC Wainwright & Co. reiterated a Buy rating with a $15 price target.
The insider purchase by the CFO suggests strong confidence in the company's future. Coupled with a Buy rating and a $15 price target from HC Wainwright & Co., this news is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100